-
Mashup Score: 0Subcutaneous Mosunetuzumab Demontrates Promising Efficacy in Previously Untreated High-Tumor Burden FL - 21 hour(s) ago
Interim results from the phase 2 MorningSun styudy show fixed-duration subcutaneous mosunetuzumab yields high response rates and manageable safety for patients with previously untreated high-tumor burden follicular lymphoma.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet
-
Mashup Score: 0
According to results from the phase 2 DEPEND trial, neoadjuvant nivolumab plus chemotherapy and response-stratified de-escalated chemoradiation demonstrated promise among patients with HPV-negative locally advanced head and neck squamous cell carcinoma.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet-
According to results from the phase 2 #DEPEND trial, neoadjuvant #nivolumab plus #chemotherapy and response-stratified de-escalated CRT demonstrated promise among patients with HPV-negative locally advanced head & neck squamous cell carcinoma. Learn more: https://t.co/hprPugQgEA https://t.co/f8sZWyWZ0x
-
-
Mashup Score: 0Zanubrutinib for Patients With del(17p) CLL and SLL: 5-Year Follow-Up From the SEQUOIA Trial - 2 day(s) ago
Constantine Tam, MD discusses 5-year follow-up results from the SEQUOIA trial evaluating the efficacy of zanubrutinib for patients with chronic lymphocytic leukemia and a chromosome 17p deletion.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet-
Constantine Tam, MD discusses 5-year follow-up results from the #SEQUOIA trial evaluating the efficacy of zanubrutinib for patients with #CLL and a chromosome 17p deletion. Learn more: https://t.co/Qx62FaOpWg https://t.co/Svhevca4h8
-
-
Mashup Score: 0FOLFIRINOX Significantly Improves Progression-Free Survival for Patients With Locally Advanced Pancreatic Cancer - 2 day(s) ago
Results from the phase 3 NEOPAN trial demonstrated that FOLFIRINOX significantly improved progression-free survival compared to gemcitabine among patients with locally advanced pancreatic cancer.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet-
Results from the phase 3 #NEOPAN trial demonstrated that #FOLFIRINOX significantly improved progression-free survival compared to #gemcitabine among patients with locally advanced pancreatic cancer. Learn more: https://t.co/aNFCPihSwH #medtwitter #onctwitter https://t.co/5UxESYcvli
-
-
Mashup Score: 1Benmelstobart Plus Chemotherapy and Anlotinib Improves Outcomes in Advanced Endometrial Cancer - 3 day(s) ago
According to results from a phase 2 trial, benmelstobart plus chemotherapy and anlotinib, followed by maintenance benmelstobart and anlotinib, improved outcomes among previously untreated patients with advanced or recurrent endometrial cancer.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet-
#Benmelstobart plus #chemotherapy and #anlotinib improved outcomes for previously untreated patients with advanced or recurrent endometrial cancer. Learn more: https://t.co/BUzBKVdNT9 #ASCO25 #medtwitter #onctwitter https://t.co/r6e4Eq6oLi
-
-
Mashup Score: 1
Based on results from the ARANOTE study, the FDA has approved darolutamide for patients with metastatic castration-sensitive prostate cancer.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet-
Based on results from the #ARANOTE trial, the @US_FDA has approved #darolutamide for patients with metastatic castration-sensitive prostate cancer. Learn more: https://t.co/ou7KDu2DpR #medtwitter #onctwitter https://t.co/1C3gLJlfY9
-
-
Mashup Score: 0Allogeneic Stem Cell Transplantation Beneficial for Patients With High-Risk or R/R Chronic Lymphocytic Leukemia - 3 day(s) ago
Allogeneic stem cell transplantation demonstrated improved survival and cancer outcomes among patients with chronic lymphocytic leukemia, according to a retrospective study.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet-
Allogeneic stem cell #transplantation demonstrated improved survival and cancer outcomes among patients with #CLL, according to a retrospective study. Learn more: https://t.co/i8bryyDnX4 https://t.co/8yV2qAz3ax
-
-
Mashup Score: 0Nivolumab Plus Relatlimab for Patients With Unresectable or Metastatic Mismatch Repair Proficient Colorectal Cancer - 3 day(s) ago
Results from a phase 2 study identified the effect that treatment with nivolumab and relatlimab has on the tumor microenvironment among previously treated patients with unresectable or metastatic mismatch repair proficient colorectal cancer.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet-
Results from a phase 2 study identified the impact of treatment with #nivolumab and #relatlimab on the tumor microenvironment among previously treated patients with unresectable or metastatic pMMR CRC. Learn more: https://t.co/O8Hopd6B97 #medtwitter #onctwitter https://t.co/uorhs5D6DJ
-
-
Mashup Score: 1Zanubrutinib Demonstrates Efficacy and Tolerability Among BTK Inhibitor Intolerant Patients With CLL/SLL - 4 day(s) ago
For patients previously intolerant to ibrutinib and/or acalabrutinib, zanubrutinib demonstrated improved safety and tolerability for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet-
For patients previously intolerant to ibrutinib and/or acalabrutinib, #zanubrutinib demonstrated improved safety and tolerability for the treatment of #CLL and #SLL. Learn more: https://t.co/YX2fqYE2am https://t.co/UmeXN3F5pd
-
-
Mashup Score: 0TAR-200 Monotherapy Demonstrates Durability of Response in BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer - 4 day(s) ago
Joseph Jacob, MD, discusses results from cohort 2 of the ongoing phase 2b SunRISe-1 trial which assessed the durability of response of TAR-200 monotherapy among patients with Bacillus Calmette-Guérin-unresponsive high-risk non-muscle invasive bladder cancer.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet-
Joseph Jacob, MD, discusses results from cohort 2 of the ongoing phase 2b #SunRISe1 trial which assessed the durability of response of #TAR200 monotherapy among patients with BCG-unresponsive high-risk non-muscle invasive bladder cancer. Learn more: https://t.co/2S6cYqPlvO https://t.co/tTIMMg2ozG
-
Interim results from the phase 2 MorningSun styudy show fixed-duration subcutaneous #mosunetuzumab yields high response rates and manageable safety for patients with previously untreated high-tumor burden #FL. Learn more: https://t.co/OuH0cvaSEe https://t.co/DP5fUREmBt